- ICH GCP
- EU klinikai vizsgálatok nyilvántartása
Legfrissebb próbák
EudraCT Number: 2020-002372-13 | Sponsor Protocol Number: SRP-9001-303 | Start Date: | ||||||||||||||||
Sponsor Name: Sarepta Therapeutics, Inc. | ||||||||||||||||||
Full Title: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of SRP-9001 in Non-Ambulatory and Ambulatory Subjects... | ||||||||||||||||||
Medical condition: Duchenne Muscular Dystrophy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male | |||||||||||||||||
Trial protocol: FR (Ongoing) SE (Ongoing) IT (Ongoing) ES (Ongoing) BE (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004897-40 | Sponsor Protocol Number: GABA-2 | Start Date: | |||||||||||
Sponsor Name: PHARM – Pharmaceutical Research Management srl | |||||||||||||
Full Title: Randomized, double-blind, placebo controlled, multi-centre, superiority phase II study to evaluate the safety, pharmacokinetic, efficacy of gabapentin liquid formulation as add-on to morphine in ch... | |||||||||||||
Medical condition: Chronic pain of neuropathic or mixed origin | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) FR (Ongoing) NL (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002339-44 | Sponsor Protocol Number: IGM-2323-001 | Start Date: | |||||||||||
Sponsor Name: IGM Biosciences, Inc. | |||||||||||||
Full Title: A Phase 1/2 Open-Label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of IGM-2323 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphomas | |||||||||||||
Medical condition: Relapsed/Refractory (R/R) Non-Hodgkin lymphomas (NHL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) ES (Ongoing) IT (Ongoing) DK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-018781-23 | Sponsor Protocol Number: 2917800009 | Start Date: | |||||||||||
Sponsor Name: Top Institute Food and Nutrition | |||||||||||||
Full Title: Diagnose of GH-deficiency: comparing the dietary-protein test with conventional Growth Hormone Stimulation Tests | |||||||||||||
Medical condition: To investigate if there is a correlation between the peak GH concentrations after ingestion of gelatin protein and the peak GH concentrations after the two standard tests (GHST) in order to discrim... | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003509-41 | Sponsor Protocol Number: GBG90 | Start Date: | |||||||||||
Sponsor Name: GBG Forschungs GmbH | |||||||||||||
Full Title: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel / carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patien... | |||||||||||||
Medical condition: Patients with triple negative or HRpositive, early breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002882-41 | Sponsor Protocol Number: AIBDSG_002 | Start Date: | |||||||||||
Sponsor Name: Medical University of Vienna (MUW) | |||||||||||||
Full Title: Sono-Response-Study A Pilot Study on the use of contrast enhanced ultrasound in Crohn’s disease | |||||||||||||
Medical condition: Inflammatory bowel disease (Crohn's disease) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-024094-39 | Sponsor Protocol Number: Adip-2010 | Start Date: | ||||||
Sponsor Name: University of Ulm, University Hospital Ulm | ||||||||
Full Title: Offene, monozentrische, nicht kontrollierte und nicht randomisierte Phase IV-Studie zur Bestimmung der Pharmakokinetik von Carbapenemen in adipösen Patienten. | ||||||||
Medical condition: The purpose of this study is to determine the free tissue kinetics of ertapenem and meropenem in fatty tissue and intraperitoneal fluid up to 24 hours after administration of the IMP. Subjects are ... | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: DE (Completed) | ||||||||
Trial results: View results |
EudraCT Number: 2005-003023-40 | Sponsor Protocol Number: 21805 | Start Date: | ||||||
Sponsor Name: Food Standards Agency | ||||||||
Full Title: The role of peanut specific T cell responses in children with peanut allergy and in children who are tolerant to peanuts | ||||||||
Medical condition: Children with Peanut Allergy | ||||||||
|
||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005019-29 | Sponsor Protocol Number: Rux-cALL-Pol_2020 | Start Date: | ||||||||||||||||
Sponsor Name: Medical University of Lodz | ||||||||||||||||||
Full Title: Single-arm interventional study with ruxolitinib and AIOEP-BFM2017 chemotherapy in children with acute lymphoblastic leukemia and confirmed activation of JAK/STAT pathway. | ||||||||||||||||||
Medical condition: Acute Lymphoblastic Leukemia with confirmed activating of JAK/STAT pathway in children and adolescents | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: PL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000730-40 | Sponsor Protocol Number: SOCRATES | Start Date: | |||||||||||
Sponsor Name: Heinrich-Heine-Universität Düsseldorf | |||||||||||||
Full Title: Phase II study evaluating transarterial chemoembolization (TACE) in combination with sorafenib for the treatment of advanced hepatocellular carcinoma (HCC) | |||||||||||||
Medical condition: histologically proven advanced hepatocellular carcinoma (HCC) not suitable for resection or liver transplantation but without extrahepatic manifestations and without previous treatment for HCC | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |